|
|
|
|
|
Tositumomab
drug data and news
Tositumomab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Tositumomab | ||
| Brand Names/Synonyms | Ig gamma-1 chain C region; Bexxar (Corixa Corp) | ||
| Indication | For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular) | ||
| Sponsored links | Description | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | |
| Pharmacology | Bexxar binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin’s lympohomas. The antibody leads to selective killing of B-cells. | ||
| Mechanism Of Action | Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation. | ||
| Tositumomab News (When available) |
International Orphan Drug Approvals: 1D09C3 and Nexavar Apr 21, 2006 Survival Improving for Patients with Stage IV Follicular Lymphoma Apr 17, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antineoplastic Agents | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Murine anti-CD20 antibody | ||
| Chemical Formula | C6416H9874N1688O1987S44 >Mouse-Human chimeric Anti-CD20 Light Chain 1 >Mouse-Human chimeric Anti-CD20 Heavy Chain 2 >Mouse-Human chimeric Anti-CD20 Light Chain 2 | ||
| Molecular Weight | 143859.7 | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.414 | ||
| Isoelectric Point | 8.68 | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production | ||
| Half Life | 0.8 hours (mammalian reticulocytes, in vitro) | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic3/bexxar.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00085 | ||
| CAS Registry Number | 192391-48-3 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | IGHG1_HUMAN (P01857) | ||
| GenBank ID | J00228 | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |